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OBJECTIVES: Everolimus and sunitinib are indicated to treat patients with 
advanced, progressive pancreatic neuroendocrine tumors (pNETs). This analysis 
examines the projected cost-effectiveness of everolimus versus sunitinib in this 
setting from a Swedish payer’s perspective. METHODS: A lifetime Markov model 
was developed to simulate a cohort of advanced, progressive pNET patients to 
estimate the incremental cost-effectiveness when treating with everolimus (10 
mg/day) versus sunitinib (37.5 mg/day). Efficacy inputs were based on a weight-
adjusted indirect comparison of the therapies using the respective phase 3 trial 
data (Signorovitch et al. 2013 and data on file). The disease pathway is reflected 
through mutually exclusive health states: stable disease without adverse events, 
stable disease with adverse events, disease progression, and death. Unit costs 
were obtained from public official Swedish sources. The model includes only 
direct costs. Resource use was based on a German physician survey, validated 
and adapted to Swedish conditions. Costs were represented in 2014 Swedish Krona 
(SEK). The incremental cost-effectiveness ratio (ICER) was calculated. Two-way 
sensitivity analyses were conducted to test the model’s robustness. RESULTS: 
In the base case, the estimated gain of everolimus over sunitinib was 0.357 LYs 
(0.261 QALYs), which results in an ICER that ranges from 100,000 -200,000 SEK/
QALY depending on the assumptions around the duration of therapy for active 
treatment. The analysis is sensitive to the uncertainty of the indirect analysis 
results and variables such as dose intensity. CONCLUSIONS: This model, based 
on an indirect comparison of phase 3 studies, indicates that everolimus is cost-
effective relative to sunitinib in advanced pNET. Its reliance on an indirect analysis 
due to the lack of head-to-head randomized controlled trial data warrants future 
research; however, model results indicate that everolimus is a valuable treatment 
option for pNET patients in Sweden.
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OBJECTIVES: The aim of the study was to analyze the cost-effectiveness of 
cetuximab compared to bevacizumab, both in combination with cytotoxic 
chemotherapy (folinic acid, fluorouracil and irinotecan, FOLFIRI), for first-line 
treatment of RAS wild-type metastatic colorectal cancer, under the public per-
spective in Brazil. METHODS: A cost-effectiveness analysis has been developed 
based on a Markov model, comparing the use of cetuximab+FOLFIRI versus 
bevacizumab+FOLFIRI. Only 2014 direct medical costs were considered in the 
analyses and outcomes were measured in terms of life years saved. Efficacy 
data were obtained from the recently published clinical trial FIRE-3, a head-
to-head trial between cetuximab+FOLFIRI and Bevacizumab+FOLFIRI, and 
costs were obtained from national databases, reflecting the perspective of the 
public healthcare sector in Brazil as a third party payer. Costs and outcomes 
were discounted to present value at a 5% annual rate. The time horizon con-
sidered 10 years. The total number of patients was calculated by the number 
of patients currently receiving chemotherapy who would be considered RAS 
wild-type and eligible to use cetuximab. RESULTS: In a 10 years time horizon, 
the use of cetuximab + FOLFIRI achieved clinical gains of 0,51 life years saved 
compared to bevacizumab + FOLFIRI, with an average cost reduction of R$1,953 
per patient. Cetuximab was shown to be a dominant therapy compared to bev-
acizumab, saving resources up to BRL 14,450,940.00 considering 5,171 patients 
in 2015. CONCLUSIONS: The use of cetuximab as first-line treatment for wild-
type RAS metastatic colorectal cancer has shown significant and clinically 
meaningful benefits while being cost-saving to the Brazilian public healthcare 
system.
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OBJECTIVES: Population-wide screening for epidermal growth factor receptor (EGFR) 
mutations and anaplastic lymphoma kinase (ALK) gene rearrangements to inform 
cancer therapy in non-small cell lung cancer (NSCLC) is recommended by guidelines. 
We estimated cost-effectiveness of multiplexed predictive biomarker screening in 
metastatic NSCLC from a societal perspective in the US. METHODS: We constructed 
a microsimulation model to compare the life expectancy and costs of multiplexed 
testing and molecularly guided therapy vs treatment with cisplatin-pemetrexed 
(CisPem). All testing interventions included a two-step algorithm of concurrent 
EGFR mutation and ALK overexpression testing with immunohistochemistry (IHC) 
followed by ALK rearrangement confirmation with a fluorescence in situ hybridiza-
tion (FISH) assay for IHC positive results. Three strategies were included: ‘Test-treat’ 
approach, where molecularly guided therapy was initiated after obtainment of test 
results; ‘Empiric switch therapy’, with concurrent initiation of CisPem and testing 
and immediate switch to test-result conditional treatment after one cycle of CisPem; 
and ‘Empiric therapy’ approach in which CisPem was continued for four cycles before 
start of a tyrosine kinase inhibitor (TKI). RESULTS: The incremental cost-effective-
ness ratio (ICER) for ‘Test-treat’ compared to treatment with CisPem was $136,000 
per quality-adjusted life year (QALY) gained. Both empiric treatment approaches 
had less favorable ICERs. ‘Test-treat’ and ‘Empiric switch therapy’ yielded higher 
expected outcomes in terms of QALYs and life-years (LYs) than ‘Empiric therapy’. 
These results were robust across plausible ranges of model inputs. CONCLUSIONS: 
From a societal perspective, our cost-effectiveness results support the value 
of multiplexed genetic screening and molecularly guided therapy in metastatic 
NSCLC.
and pharmacoeconomic analysis results were validated by probabilistic sensitiv-
ity analysis. CONCLUSIONS: Sorafenib is cost-effective for treatment of patients 
with RAI refractory locally advanced/metastatic DTC compared to BSC with an 
ICER value below the willingness-to-pay threshold (3-times GDP per capita ─ 32,346 
USD) for Turkey.
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OBJECTIVES: To evaluate the cost-effectiveness of primary prophylaxis (PP) with 
pegfilgrastim vs lipegfilgrastim to reduce the incidence of febrile neutropenia (FN) 
in patients with stage II breast cancer receiving 4-cycle TC (docetaxel, cyclophos-
phamide) and patients with non-Hodgkin lymphoma receiving 6-cycle R-CHOP 
(rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) over a life-
time horizon from a Belgian payer perspective. METHODS: A Markov cycle tree 
model tracks FN events during chemotherapy (3-week cycles) and long-term sur-
vival (1-year cycles). Model inputs include: the odds ratio of FN between lipegfil-
grastim PP and pegfilgrastim PP (median [95% credible interval]: 1.39 [0.54–3.50]), 
estimated from a meta-analysis of randomized controlled trials using mixed-
treatment comparison; equivalent prices of lipegfilgrastim and pegfilgrastim since 
the launch of lipegfilgrastim in Belgium (August 2014); mortality (which is affected 
by FN and chemotherapy relative dose intensity); costs (in 2014 € ); and utilities. 
All inputs were estimated from public sources, research databases, and peer-
reviewed publications. Quality-adjusted life-years (QALYs) and expected lifetime 
costs were estimated for each strategy. Probabilistic sensitivity analyses (PSA) 
and scenario analyses were conducted. RESULTS: Pegfilgrastim PP dominated 
lipegfilgrastim PP, with total lifetime costs of € 7,482 vs € 7,806 for TC and € 19,149 
vs € 19,801 for R-CHOP and total lifetime QALYs of 13.379 vs 13.348 for TC and 
4.241 vs 4.184 for R-CHOP. At a willingness-to-pay threshold of € 30,000 per QALY, 
pegfilgrastim PP was cost-effective vs lipegfilgrastim PP in approximately 75% of 
PSA simulations for both regimens. In a scenario analysis when the lipegfilgrastim 
price was set at 90% that of pegfilgrastim, the incremental cost-effectiveness 
ratios for pegfilgrastim PP vs lipegfilgrastim PP were € 4,700 per QALY gained for 
TC and € 857 per QALY gained for R-CHOP. CONCLUSIONS: From a Belgian payer 
perspective, pegfilgrastim PP is cost-effective vs lipegfilgrastim PP in patients with 
stage II breast cancer receiving TC and in patients with non-Hodgkin lymphoma 
receiving R-CHOP.
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We also evaluated small and large shift scenarios of 7.8% and 20.2%, respectively. 
We calculated the incremental QALYs, costs, and cost-effectiveness ratio (ICER) in 
each scenario. RESULTS: The assay strategy was dominant in all scenarios evalu-
ated. In the 5-year and lifetime horizon analyses, the assay resulted in 0.02 and 0.04 
more QALYs and $780 and $730 less in costs, respectively. The small and large shift 
scenarios resulted 0.02 and 0.05 more QALYs, and $5 and $1,300 less in costs over 
a lifetime horizon, respectively. The ICER was most sensitive to the assay cost, the 
AS health state utility, and the proportion of low-risk patients receiving AS in usual 
care. CONCLUSIONS: Our results suggest that the 8-protein prognostic assay is 
potentially cost-effective vs. usual care in patients with Gleason 3+3 & 3+4 prostate 
cancer. Future studies will evaluate the impact of the assay on patient/physician 
treatment choices in real-world settings.
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OBJECTIVES: To perform a cost-effectiveness analysis of Panitumumab+FOLFOX vs 
Bevacizumab+FOLFOX as first-line treatment on RAS-WT mCRC patients from the 
Mexican public healthcare system perspective. METHODS: The evaluation was per-
formed using a Markov model that simulates a hypothetical cohort of patients over 
seven health-stages in two-week transition cycles. Progression-free survival (PFS) 
and overall survival (OS) were used as reported in the PEAK trial. Resource use was 
obtained from five oncologists at four public healthcare institutions. Costs include 
chemotherapy, follow-up, adverse events, metastasis resection, second-line treat-
ment, palliative care, and funeral costs. Mexican Social Security Institute costs were 
applied. Costs and benefits are discounted at 5% for a 10-year time line. Additionally, 
a cost-minimization vs Cetuximab was performed due to equivalence in OS described 
in the ASPECCT trial and similar values of PFS and OS reported in first line for compa-
rable populations. RESULTS: The total costs are $1,048,009.42 for Panitumumab (mean 
life of 3.47 years), and $872,201.70 for Bevacizumab (mean life of 2.80 years), with a 
mean cost-effectiveness ratio per month of OS of $25.173 and $25.932, respectively. 
The 10-month projection for anti-EGFR therapies reveals a total cost of $779,873.60 
for Panitumumab and $1,119,871.90 for Cetuximab, which represents savings of 
$339,998.30 (30.4%) per patient. CONCLUSIONS: Panitumumab as first-line treat-
ment improves the clinical parameters of RAS-WT mCRC patients and presents a 
mean cost-effectiveness ratio similar to Bevacizumab in this population. Regarding 
to Cetuximab, Panitumumab is a cost-saving strategy, with reduction in total costs of 
treatment and administration for public healthcare institutions in Mexico.
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OBJECTIVES: Colorectal cancer is the second cause of cancer-related mortal-
ity worldwide. In Brazil, the National Cancer Institute estimated the occurrence 
of 32,600 new colorectal cancer cases (15,070 cases in males and 17,530 cases in 
females) for 2014. Considering the disease impact and the recent findings of relevant 
clinical trials under new biomarkers’ evaluations in the RAS gene, we developed a 
cost-effectiveness analysis evaluating the use of cetuximab in combination with 
FOLFIRI (folinic acid, fluorouracil and irinotecan) compared to FOLFIRI alone for met-
astatic colorectal cancer (mCRC) in RAS wild-type patients, in the public health care 
system in Brazil. METHODS: To estimate the costs and outcomes of the treatments 
we designed a Markov model in which patients with mCRC were evaluated consider-
ing the natural course of the disease during a time horizon of 10 years. The outcomes 
were evaluated in terms of life year saved. Efficacy data was retrieved primarily from 
the CRYSTAL trial, recently evaluated in light of the new RAS biomarker. Only direct 
2014 medical costs were considered. Costs were obtained from the public database 
DATASUS. Costs and outcomes were discounted to present value at a 5% annual 
rate. RESULTS: In the comparison with cetuximab+FOLFIRI vs FOLFIRI, the incre-
mental effectiveness estimated was 0.7 life years, with an incremental cost of BRL 
46,007.34, representing a cost-effectiveness ratio of 66,090.91. Considering a GDP per 
capita of BRL 24,065.00, the ICER calculated could be considered cost-effective since 
it would fall under the threshold of 3 times the GDP per capita. CONCLUSIONS: 
Cetuximab+FOLFIRI has shown to be cost-effective in mCRC RAS wild-type patients, 
enabling a significant and clinically meaningful increase in survival supported by 
the new findings from the CRYSTAL trial in the RAS population subgroup.
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OBJECTIVES: To evaluate the cost-effectiveness of conventional Transarterial 
chemoembolization with Lipiodol (cTACE) compared to Drug-Eluting-Bead-
Chemoembolization (DEB TACE) in patients with hepatocellular carcinoma (HCC) from 
the Ministry of health perspective. METHODS: A decision tree model was developed 
based on the Egyptian clinical practice, and was derived from published sources. This 
decision analytical model was constructed to assess the costs and consequences 
associated with cTACE compared with DEB TACE. The clinical parameters were derived 
from a comparative study previously published. Direct medical costs were obtained 
from the Ministry of health hospitals in Egypt. Deterministic sensitivity analyses 
were conducted. No discounting was conducted. RESULTS: The total survival days of 
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OBJECTIVES: To analyze the cost-effectiveness of imatinib as first-line therapy from 
2016-2021 compared to physician’s choice of other approved second-generation 
tyrosine kinase inhibitors (TKIs) dasatinib or nilotinib in chronic myeloid leukemia 
in chronic-phase (CML-CP), once imatinb loses patent exclusivity. METHODS: A 
Markov model simulating “imatinib-first” compared to “physician choice” in treat-
ing CML-CP in 2016 through 5 years from the U.S. commercial payer perspective. 
In both approaches, if initial treatment fails, patients are switched to second-gen-
eration TKIs. Patients switch if they fail efficacy endpoints: 12-month complete 
cytogenetic response (CCyR); or 3-month early molecular response (EMR). Patients 
are then followed from switching through overall survival. They can also dete-
riorate to accelerated phase/blast crisis or death. The model assumes stabilized 
prices of second-generation TKIs, but adjusts the price of imatinib to be 100% of 
the branded price for first 6-months, 60-80% for the second 6-months and 10-30% 
thereafter based on patent expiration. For each drug, probabilities of treatment 
choice, switching and failure were meta-analyzed from published clinical trials. 
Quality-adjusted life years (QALYs) were based on US-societal health utilities. Direct 
medical costs per patient were calcated from Marketscan commercial claims (2011-
2012), including annual drug prices. 2013 U.S.-dollars and QALYs were discounted 
at 3%. Univariate and multivariate sensitivity analyses tested parameters with 
greatest impact on results. Findings were interpreted from a willingness-to-pay of 
$100,000/QALY. RESULTS: Based on a 12-month CCyR, imatinib-first ($270,772; 3.80 
QALYs) was cost-effective compared to physician choice ($361,935; 3.93 QALYs), an 
incremental cost-effectiveness ratio (ICER) of $701,000/QALY. The ICER based on 
3-month EMR was $470,000/QALY. Results were robust to uncertainty. The proba-
bilistic sensitivity analysis demonstrated that imatinib-first was cost-effective in 
99% of simulations. CONCLUSIONS: When imatinib loses patent protection in 2016 
in the U.S. and its price declines, it will be the cost-effective treatment strategy for 
CML-CP compared to dasatinib and nilotinib.
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OBJECTIVES: Patients with HER2-positive metastatic breast cancer (MBC) who 
receive Trastuzumab and/or taxanes often need treatment with different agents, 
such as Ado-trastuzumab emtansine (TDM-1) or a combination of Lapatinib and 
Capecitabine (L+C), when disease progresses. Although TDM-1 has better efficacy in 
improving survival, its high cost compared to L+C needs further economic evalua-
tion. This study aimed to assess the cost-effectiveness of TDM-1 compared to L+C in 
MBC patients from a U.S. payer’s perspective. METHODS: A Markov model depicting 
MBC progression for a total of 120 21-day treatment cycles (6.9 years) was devel-
oped. Clinical endpoints in the model included progression-free survival and overall 
survival. The model included the impact of disease progression and toxicity from 
cancer drugs. Cancer drug toxicities included were thrombocytopenia, neutropenia, 
hepatotoxicity, peripheral neuropathy, and pulmonary toxicity. Effectiveness inputs 
were derived from a Phase-III clinical trial comparing TDM-1 and L+C; cost and 
utility inputs from published literature and expert opinion. All cost inputs were 
expressed in 2014 U.S. dollars. The incremental cost-effectiveness ratio (ICER) was 
calculated using quality-adjusted life years (QALY) as the effectiveness measure. 
One-way sensitivity analyses were performed. RESULTS: Patients receiving TDM-1 
cost $241,109 with 1.88 QALYs gained over the 6.9 years, compared with $200,541 
and 1.56 QALYs in L+C group. The base-case ICER was $124,247/QALY. Compared 
to L+C, patients treated with TDM-1 had an expected 0.45 years longer survival 
and 0.31 years longer progression-free survival. The ICER varied from $70,270 to 
$178,223 per QALY when the TDM-1 cost changed from 80 to 120% of its current 
price. CONCLUSIONS: The determination of TDM-1 being cost-effective for MBC 
patients depends on the willingness-to-pay threshold used. Patients derived sig-
nificant life expectancy gains from TDM-1, leading to longer treatment with this 
costly agent.
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OBJECTIVES: Clinico-pathologic factors alone are insufficient to predict the likeli-
hood of progression of Gleason 3+3 & 3+4 prostate cancer. Therefore, many patients 
receive treatment, despite having unaggressive tumors. A novel prognostic assay 
(ProMark™) that uses quantitative measurements of protein biomarkers has been 
validated to predict prostate cancer aggressiveness at the time of biopsy. Our objec-
tive was to evaluate the potential cost-effectiveness of using this 8-protein assay to 
inform treatment decisions. METHODS: We developed a Markov model to estimate 
quality-adjusted life-year (QALY) and cost outcomes for assay and usual care (NCCN 
guidelines) strategies over 5-year and lifetime horizons. The proportion of patients 
classified as low, intermediate, and high-risk for each strategy was derived from 
the assay’s validation study. Treatment distributions, costs, utilities, and mortality 
were derived from the peer-reviewed literature. In the base case, we assumed an 
increase in the use of active surveillance (AS) vs treatment of 14.5% (vs usual care). 
